NYSE · Healthcare · Diagnostics & Research · USA
Agilent Technologies Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Agilent Technologies supplies instruments, reagents, software and consumables for laboratory analysis across life sciences, diagnostics and applied markets. Its three segments serve pharmaceutical, clinical and academic customers with solutions for molecular analysis, contract manufacturing of therapeutics, quality control testing and chemical identification. The company distributes products globally through direct sales and channel partners.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Agilent Technologies Inc stock.
Overvalued: intrinsic value $80.08 per share, market price $169.90, margin of safety -112.2% (as of 2026-10-19).
Discounting its cash flows at 10.5% (average of 3 methods) values the shares at $80.08; the price of $169.90 is 112% above that value, and 71% of that value comes from beyond year five.
Leak Score: 49/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
7 more in this industry show a wider margin of safety.
A is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.5% (average of 3 methods) values the shares at $80.08; the price of $169.90 is 112% above that value, and 71% of that value comes from beyond year five.
$80.08 per share (as of the 2026-10-19 close), against a market price of $169.90. That is a margin of safety of -112.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
49 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.